Theralink Tumor Biomarker Platform
The Theralink assay uses Reverse Phase Protein Array (RPPA) technology to measure the abundance and activation of cell surface receptor proteins and their downstream signaling pathways. These biomolecules serve as the drug targets for most FDA-approved and investigational therapies for cancer. Theralink is intended to aid in determining the ideal prescribed medication for patients based on the unique molecular characteristics of their cancer.
Our highly sensitive analyses of identified biomarkers has the potential to empower physicians to improve treatment decisions through better prediction of treatment outcomes. The biomarker information might prevent the patient from being exposed to cytotoxic treatments that may be unlikely to deliver clinically meaningful benefits, while guiding physicians to prescribing treatments that may be likely to yield maximum results.
The Theralink platform can be used for multiple applications in therapeutic clinical trials including:
- Patient selection and stratification
- Mechanism of Action (MOA) evaluations
- Identification of compensatory and resistance pathways
- Pharmacokinetic/pharmacodynamic (PK/PD) end point measurements
Theralink measures phosphorylated proteins in tumor tissues. Phosphorylated proteins represent active targets for drugs. Examples of tumor indications for application development include, but are not limited to:
- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Non-Small Cell Lung Cancer
However, please inquire with our team about your indication of interest.